Business Wire

Leicester’s Hospitals Awards Deenova a Unit Dose Pharmacy Automation 15 Year Contract

2.8.2021 09:00:00 EEST | Business Wire | Press release

Share

Deenova reported today it signed its first ever contract in the United Kingdom, and established operations in Europe’s second largest GDP health care market, with the NHS being the eight largest employer in the world. Deenova was selected by University Hospitals of Leicester NHS Trust as the best solution amongst 8 of Deenova's competitors in United Kingdom and the United States of America.

Claire Ellwood, chief pharmacist at University Hospitals of Leicester NHS Trust, said: “We’re proud to be working with Deenova to deploy the first unit dose closed loop medicines management system in the UK. Every year, we administer millions of medication doses so it’s vital our processes are as safe and efficient as possible. The partnership with Deenova will increase automation within our medication processes helping to reduce errors and wastage as well as freeing up staff time for other care and tasks. After a successful pilot, we are pleased to start planning the roll out across our three hospitals. This programme will ensure the right medicines are in the right place at the right time and will undoubtedly improve care for our patients.”

Giorgio Pavesi, Managing Director of Deenova in Italy stated: “I am extremely proud of the teamwork and dedication exhibited by our employees and those of University Hospitals of Leicester NHS Trust, proving to the health care industry the patient safety and economic advantages of Deenova´s unique Closed-Loop Medication Unit Dose management system and services, as evidenced by the report issued by the East Midlands Academic Health Science Network (AHSN) undertaking an 18 month evaluation of Deenova solutions. The published results included: 25% reduction in the consumption (and costs) of medicines; 40% reduction in the number of items held in the ward stock cupboard, 60% reduction in medicines wastage, and a reduction in missed doses due to medicine not available on wards from 10% to 1.2%, amongst other patient safety and economical benefits, leading to this award.”

Deenova plans to fulfill University Hospitals of Leicester NHS Trust’s contract award with delivery, installation and full service/support for 3 All-in-1 and 1 Acced Packaging Robots, 56 All-in-1 Station Medication Dispensing Robots, and more than 100 All-in-1 Trolleys with secure bed-side verification.

East Midlands AHSN Commercial Director, Tim Robinson, said: “A key role of AHSNs is to help build collaboration across sectors, and in particular to connect commercial innovators with the heath and care organisations that could benefit from their innovations. With this in mind, we welcome the progress made in Leicester - this is a great example of how the NHS and commercial sector can work in partnership. As well as the potential to benefit patients and generate efficiencies, we also welcome the investment into the East Midlands and the jobs this partnership will create.”

Information

Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and making the best use of staff time. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.

University Hospitals of Leicester NHS Trust : Every day at Leicester’s Hospitals we save lives, improve lives and usher in new life. We want to continue to improve everything that we do, so that we can achieve our vision: Caring at its best for every patient, every time. As one of the largest NHS Trusts in the country, our contribution goes beyond health; we are the largest employer in our region, we educate and train the staff of the future, push the boundaries of research and with our £1bn turnover are an economic engine for East Midlands and beyond. This is a particularly exciting time for Leicester’s Hospitals. We have been given £450m to reconfigure services and build new hospitals. This will include a new Children’s Hospital, Maternity Hospital, Treatment Centre and two new Intensive Care Units. For more information please visit: www.leicestershospitals.nhs.uk

The East Midlands Academic Health Science Network (EMAHSN) is one of 15 Academic Health Science Networks in England that operate as the innovation arm of the NHS. AHSNs bring together the NHS, universities, industry and social care to transform health and stimulate economic growth. In the East Midlands our current priorities focus on identifying and spreading innovations that respond to the COVID-19 pandemic and the recovery of services, along with priority themes including mental health, patient safety and optimising medicines. For more information please visit: www.emahsn.org.uk

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts at Deenova:
Christophe Jaffuel, Martina Buccianti
m.buccianti@deenova.com, +39 0523 785311

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 18:20:00 EET | Press release

3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Systems’ largest potential new product launches: the NextDent® Jetted Denture Solution. This solution forms the cornerstone of the Company’s ‘replac

Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 18:00:00 EET | Press release

Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the Canton Network, applying the same trusted and reliable standards it uses to operate critical payment systems today. Institutions can experiment with and scale stablecoin payments,

Andersen Consulting Adds Collaborating Firm Stratis Consulting in Ireland25.3.2026 15:30:00 EET | Press release

Andersen Consulting enters into a Collaboration Agreement with Stratis Consulting, a Dublin-based firm specializing in strategic employment relations, people strategy, and workplace policy. Founded in 2017, Stratis Consulting is an advisory firm recognized for its deep expertise in employment relations and leadership strategy. The firm works closely with senior executives, boards, and HR leaders as a trusted advisor to design practical, people-centered solutions that improve engagement, strengthen leadership effectiveness, and align workforce strategy with long-term business objectives. Stratis Consulting supports organizations navigating M&A activities and major changes in the company to ensure effective practice and implementation of workforce strategies. “At Stratis, we believe that people strategy enabled by successful employment relations is business strategy,” said Brendan McGinty, managing partner of Stratis Consulting. “Our goal is to help organizations recognize the value of s

ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 15:30:00 EET | Press release

ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Regional CEO, Europe, ECU Worldwide, said “With the expansion of XLERATE 2.0, we are offering our customers a de

Incyte Announces Executive Leadership Appointments25.3.2026 15:00:00 EET | Press release

Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye